ID   KMS-34-SCC2
AC   CVCL_A5SB
SY   KMS34-SCC2; SCC2
DR   cancercelllines; CVCL_A5SB
DR   Wikidata; Q107115594
RX   PubMed=29045832;
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Trp146Ter (c.438G>A); ClinVar=VCV000428890; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2996 ! KMS-34
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 19-12-24; Version: 7
//
RX   PubMed=29045832; DOI=10.1016/j.celrep.2017.09.078; PMCID=PMC5706555;
RA   Ezponda T., Dupere-Richer D., Will C.M., Small E.C., Varghese N.,
RA   Patel T., Nabet B., Popovic R., Oyer J., Bulic M., Zheng Y.-P.,
RA   Huang X.-X., Shah M.Y., Maji S., Riva A., Occhionorelli M., Tonon G.,
RA   Kelleher N.L., Keats J.J., Licht J.D.;
RT   "UTX/KDM6A loss enhances the malignant phenotype of multiple myeloma
RT   and sensitizes cells to EZH2 inhibition.";
RL   Cell Rep. 21:628-640(2017).
//